ESPR stock is the Next Multi-Bagger 1500% gains expected Says Hedge Fund Armistice Cap and Could gain up to 20,000% By Selling 2 FDA Approved Drugs set to be Blockbusters.

This stock will make anyone who buys it now huge amount of money, I have done extensive research on $Esperion Therapeutics(ESPR.US)$ and my friend is a CVS pharmacist says now Insurance is covering and CVS is stocking the drugs. ESPR sells 2 statin alternative medications NEXLIZET and NEXLETOL, Satin drugs are the #1 selling drugs in the world, 70 to 90 million Americans take Statin drugs and 18 million Americans are maxed out taking a Statin and need to take a PCSK9 injection or take an oral pill with just 3 options ESPR's 2 drugs or Ezetimibe. ESPR partner Daiichi Sankyo Europe DSE is selling under a different label name and now out selling PCSK9 drugs with script growth of 127%. now has 158,000 scripts up 35,000 in 3 months shown by ESPR earnings reported on Nov 7th last week, also DSE owes $300 million for a milestone payment and another $900 million on label change to ESPR, ESPR stock has tanked from $6 to under $2 in March this year when DSE said they weren't paying the $300 milestone saying the drug was not effective above 15% DSE owed $200 million if 15% to 19% effective of $300 millio above 20% this is NEXLETOL which is Bempedoic Acid and reported by New Engalnd Journal is 23% effective. I personally paid a pattern and contract attorney and he actually bought ESPR stock after OCT 25th because he is 100% confident after reviewing ESPR will get paid. A NY Judge is going to rule based on the contract agreement after November 22nd 2023. ESPR Stock could run up to $4 a share this year on the ruling, its 90c now and the company is valued under $100 million, they have $140 million in yearly sales and next year presciption growth will surge because of label change for primary prevention is expected by March 31st 2024. Esperion has total of $1.8 billion in milestone agreements. Label change will get ESPR to over 1 million yearly prescriptions would be $4 billion in yearly sales and the stock would get to $40 a share. A Hedge fund named Two Seas Capital recently disclosed a 7.4% stake in ESPR, Two Seas focuses on litigation so this is a big vote of confidence ESPR will win the judgement and be awarded the $300 million. 9 Analysts rate BUY with average $14 price target. Like I said 18 million Americans are maxed out on statin drugs and 14 million Americans are Statin intolerant. My wife now takes Nexlizet we have a $40 copay, the drug would cost $480 per month. She used to take $Amgen(AMGN.US)$ Repatha PCSK9 injections but switched to Nexlizet and has no side effects. Steve Cohen #5 richest hedge fund owns 5% of ESPR. Institutions and hedge funds own 85% of ESPR. Armistice has a 9% stake and has a $15 1 year valuation. The CEO of ESPR is Sheldon he worked 25 years at $Merck & Co(MRK.US)$ go to ESPR website, he launched Ezetimibe 20 years ago which was a block buster drug. He had a presentation on Sept 11 this year shown on the website and shows that ESPR expects its drugs to be blockbusters and the CEO himself takes NEXLIZET. ESPR drug NEXLIZET is a combination of Ezetimibe. The unique way this drug works it doesn't cause side effects like Statin drugs and a HUGE benifit is both NEXLIZET and NEXLETOL don't effect Diabetic patients like Statin drugs do. My wife has a LDL reduction of over 55% using NEXLIZET so I know the drug will be a blockbuster because it works better than any Statin without the muscle pain she had. ESPR will generate returns like $Regeneron Pharmaceuticals(REGN.US)$ and $Moderna(MRNA.US)$ have done for investors. People that bought $GameStop(GME.US)$ and $AMC Entertainment(AMC.US)$ stocks should research ESPR. Go to Youtube and search Esperion Therapeutics, watch the videos from 8 years ago on Mad Money JIM cramer himself is now reported to take NEXLIZET. Search Bempedoic Acid CBS News. you will see Dr Steven Nissen who was in charge of the study saying "this will change the practice of medicine" Google Dr Steven Nissen times magazine, he is a top 100 Doctor. buying ESPR now is like buying $Netflix(NFLX.US)$ at $6 or buying $Tesla(TSLA.US)$ or $Amazon(AMZN.US)$ or $Apple(AAPL.US)$ when they were super cheap years ago. Finding incredible investments takes time to research. You can't find another $100 million company like ESPR that has $1.8 billion in future milestones and 15% royalties shown on partners page on it's website. And has 2 FDA approved drugs that will surge in sales to possibly $20 billion per year within 5 years selling yearly prescriptions to 5 million patients per year is just about 7% of the Statin market and would but this stock at $200 a share. Go to Stocktwits and follow Brinks the fund manager that bought $SBA Communications Corp(SBAC.US)$ and $Advanced Micro Devices(AMD.US)$ HE MADE $72 MILLION.